US equities |
SPCX $144.75 ▼-9.14% MU $856.49 ▼-6.26% NVDA $212.21 ▼-4.40% META $648.85 ▼-6.98% TSLA $374.58 ▼-3.08% AAPL $348.22 ▲+1.23% AMD $507.93 ▼-8.10% SNDK $1,260.93 ▼-8.51%
FinancialContent

Articles published by IMV Inc.

< Previous 1 2 Next >
News headline image
IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Names Michael P. Bailey Chairman of The Board
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. to Present at Two Upcoming Investor Conferences
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. to Present at Two Upcoming Investor Events
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Appoints Andrew Hall as Chief Executive Officer
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Announces Chief Financial Officer to Retire
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. to Present at Three Investor Conferences in September
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Announces CEO Transition
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV to Participate in the BTIG Virtual Biotechnology Conference
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Closes Previously Announced Public Offering
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
News headline image
IMV Inc. Announces Pricing of Public Offering
From IMV Inc.
Via Business Wire
Tickers IMV TSX:IMV
< Previous 1 2 Next >